Vanguard Global Advisers
ANTX icon

Vanguard Global Advisers’s AN2 Therapeutics ANTX Stock Holding History

Vanguard Global Advisers’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.5K Hold
7,334
– – ﹤0.01% 3176
2026
Q1 		$25.1K Buy
+7,334
New +$15.1K ﹤0.01% 3246

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Global Advisers's ANTX Position: Q2 2026 in Review

Vanguard Global Advisers held its AN2 Therapeutics (ANTX) position steady in Q2 2026 at 7,334 shares worth $35.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3176.

Vanguard Global Advisers first reported a position in ANTX in Q1 2026 and has held it in 2 quarters since. 59 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • Vanguard Global Advisers held 7,334 shares of AN2 Therapeutics worth $35.5K as of Q2 2026.
  • Vanguard Global Advisers left its AN2 Therapeutics share count unchanged in Q2 2026.
  • AN2 Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3176 holding.
  • Vanguard Global Advisers first reported a position in AN2 Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 59 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.